Are there any new treatments for **vulvovaginal atrophy (VVA)**?
Yes, Ospemifene is a newer selective estrogen receptor modulator (SERM) that has been approved for the treatment of moderate to severe dyspareunia (pain during intercourse) due to vulvovaginal atrophy. It works by mimicking the effects of estrogen on vaginal tissues, thereby alleviating symptoms without the risks associated with systemic estrogen therapy.
